Gilead’s Response to COVID-19

Gilead is focused on deploying our resources and decades of antiviral expertise to help patients and communities fighting the COVID-19 pandemic. As a pioneer and leader in antiviral drug development, Gilead developed the first antiviral drug approved to treat COVID-19 and continues to invest in this medicine and research that will prepare us for emerging pandemic threats. 

More than 20 Phase 3 and Phase 4 studies are underway to further evaluate the potential of our COVID-19 antiviral treatment in the management of COVID-19 disease. Gilead is also supporting more than 50 independent research studies and collaborative projects to better understand SARS-CoV-2 and the COVID-19 disease state.   

Gilead continues to collaborate with global health authorities, government agencies, healthcare systems, academic institutions, nonprofit organizations, and individual researchers and clinicians to share and update information and to bring the full weight of our science to help end this pandemic. 

Continuing Study

We continue to study our COVID-19 antiviral as a potential treatment in hospitalized populations with specific unmet needs, including people with renal impairment, children and pregnant women. For non-hospitalized people with COVID-19, we are committed to continuing to develop our investigational oral compounds and have initiated a Phase 1 trial for our novel oral COVID-19 compound. 

Enabling Access

Learn more about our access partnerships

Read about how we helped respond to the COVID-19 pandemic responsibly

For More Information

Please contact Gilead via email with any questions by clicking here.

Last Updated: Nov. 16, 2022